title: Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection.
abstract: OBJECTIVE
  To review the literature for the treatment of hepatitis C virus (HCV) genotype 1 in certain populations of patients that require further considerations before therapy initiation.
  
  
  METHODS
  A systematic electronic literature search using the MEDLINE database was performed using the search terms hepatitis C, chronic hepatitis C, drug therapy, end stage liver disease, liver transplantation, HIV, hepatitis B, African Americans, renal insufficiency, obesity, pregnancy, and pediatrics.
  
  
  METHODS
  English language studies from January 1985 to March 2015 were considered. Additional references were identified from ongoing trials obtained from clinicaltrials.gov, conference proceedings, online databases, and citations in relevant review articles.
  
  
  METHODS
  Direct-acting antivirals are first-line recommendations for the treatment of HCV genotype 1 infection, and these include combinations of sofosbuvir, simeprevir, ledipasvir/sofosbuvir, ombitasvir/paritaprevir/ritonavir plus dasabuvir, and ribarvirin. Historical and clinical data focusing on the treatment of HCV with these agents in the following populations were selected: decompensated cirrhosis, post-liver transplant, HIV, African Americans, obesity, hepatitis B coinfection, renal impairment, pregnancy, and pediatrics.
  
  
  CONCLUSIONS
  Depending on the population studied, clinicians must consider differences in efficacy outcomes, potential drug interactions, and adverse effects that patients may experience.
authors.affiliation: Temple University School of Pharmacy, Philadelphia, PA, USA toussaka@temple.edu.
authors.forename: Kimberly A
authors.initials: KA
authors.lastname: Toussaint-Miller
authors.affiliation: Temple University School of Pharmacy, Philadelphia, PA, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Andres
mesh_terms: D001741:Black or African American; D000998:Antiviral Agents / Q000627:therapeutic use*; D060085:Coinfection; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy; D016174:Hepacivirus / Q000235:genetics*; D006509:Hepatitis B / Q000188:drug therapy; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy / Q000821:virology; D006801:Humans; D018445:Infectious Disease Transmission, Vertical; D007674:Kidney Diseases / Q000150:complications / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000209:etiology; D016031:Liver Transplantation; D009765:Obesity / Q000150:complications; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy
chemical_list: D000998:Antiviral Agents
keywords: HIV/AIDS; drug interactions; hepatitis C; infectious diseases; transplants